Background {#Sec1}
==========

Adenosine is a purine nucleoside whose relevance in the central nervous system is mainly due to its role in regulating neurotransmitter release \[[@CR1]\]. The effects of adenosine are mediated by specific G-protein-coupled receptors (GPCRs) that are coupled to either G~s~ or G~i~ heterotrimeric G~αβγ~ proteins. The endogenous adenosine acts on four receptor subtypes -- A~1~R, A~2A~R, A~2B~R, and A~3~R. Convergent and compelling evidence shows that GPCRs may form complexes constituted by a number of equal (homo) or different (hetero) receptor protomers \[[@CR2]\]. As agreed in the field, a GPCR heteromer displays characteristics that are different from those of the constituting protomers, thus giving rise to novel functional entities \[[@CR3]\]. Adenosine receptors have been used as a paradigm in the study of receptor homo- and heteromerization. For instance, A~1~R, which is G~i~ coupled, and A~2A~R, which is G~s~ coupled, form a functional heteromer \[[@CR4]\].

The A~1~R-A~2A~R heteromer (A~1~-A~2A~Het) is found presynaptically in, inter alia, cortical glutamatergic terminals innervating the striatum and functions as a switch that differentially senses high and low concentrations of adenosine in the inter-synaptic space. Since adenosine has higher affinity for A~1~R than for A~2A~R, low concentrations predominantly activate A~1~R, engaging a G~i~-mediated signaling, whereas higher adenosine concentrations also activate A~2A~R, engaging a G~s~-mediated signaling \[[@CR4]\]. The physiological role of such a concentration-sensing device is remarkable as it allows adenosine to fine-tune modulate the release of neurotransmitters from presynaptic terminals. However, the mechanism by which A~1~-A~2A~Het integrates both G~i~- and G~s~-dependent signals is not yet understood. We have recently shown, using a combination of single-particle tracking experiments, bioluminescence resonance energy transfer (BRET) assays, and computer modeling, that the (minimal) functional A~1~-A~2A~Het/G protein unit is composed by a compact rhombus-shaped heterotetramer (with A~1~R and A~2A~R homodimers) bound to two different interacting heterotrimeric G proteins (G~s~ and G~i~) \[[@CR5]\]. In the present study, we aim to understand the molecular intricacies underlying the signaling mediated by A~1~-A~2A~Het, in which (1) both receptors constituting the heteromer are activated by the same endogenous agonist and (2) is coupled to two different G proteins with opposite effects, i.e., one mediating the inhibition of the adenylate cyclase (G~i~) and another mediating the activation of the enzyme (G~s~). Our data identifies a new mechanism of signal transduction and provides the molecular basis to understand the unique properties of this heteromer, in which the C-terminal tail of the A~2A~R influences the G~i~-mediated signaling of the partner A~1~R receptor.

Results {#Sec2}
=======

Homodimerization of A~1~R and A~2A~R occurs through the transmembrane (TM) 4/5 interface and heterodimerization via the TM5/6 interface in the A~1~-A~2A~Het {#Sec3}
------------------------------------------------------------------------------------------------------------------------------------------------------------

Our recently published BRET-aided computational model of the A~1~-A~2A~Het predicted the TM interfaces involved in homo- (TM4/5) and heterodimerization (TM5/6) \[[@CR5]\]. To further confirm this arrangement, we used synthetic peptides with the sequence of TM domains of the A~2A~R (abbreviated TM1 to TM7) and the A~1~R (abbreviated TM5 to TM7), fused to the cell-penetrating HIV transactivator of transcription (TAT) peptide \[[@CR6]\], to alter inter-protomer interactions in the A~1~-A~2A~Het. These peptides were first tested in bimolecular fluorescence complementation (BiFC) assays in HEK-293 T cells expressing receptors fused to two complementary halves of YFP (cYFP and nYFP) (see Methods). We detected fluorescence in HEK-293 T cells transfected with cDNAs for A~2A~R-nYFP, A~2A~R-cYFP, and non-fused A~1~R (broken lines in Fig. [1a](#Fig1){ref-type="fig"}), indicating the formation of the A~2A~R-A~2A~R homodimer. Notably, in the presence of interference peptides, we observed a fluorescence decrease only with TM4 and TM5 of A~2A~R (Fig. [1a](#Fig1){ref-type="fig"}), but not with A~1~R TM peptides (Fig. [1a](#Fig1){ref-type="fig"}) or with peptides derived from the orexin receptor (Additional file [1](#MOESM1){ref-type="media"}: Figure S1A) used as negative controls. Further negative controls show that A~2A~R peptides do not alter fluorescence in HEK-293 T cells expressing A~1~R-nYFP and A~1~R-cYFP (Additional file [1](#MOESM1){ref-type="media"}: Figure S1B). These results therefore confirmed the TM4/5 interface for A~2A~R homodimerization in the heteromer. Similarly, we detected fluorescence in cells expressing A~1~R-nYFP and A~2A~R-cYFP (broken lines in Fig. [1b](#Fig1){ref-type="fig"}), indicating formation of the A~1~-A~2A~Het. This fluorescence was only reduced in the presence of TM4, TM5, and TM6 peptides of A~2A~R (Fig. [1b](#Fig1){ref-type="fig"}). The involvement of TM5/6 in the heteromer interface was also confirmed by the fact that TM5 and TM6, but not TM7, of A~1~R reduced fluorescence in cells expressing A~1~R-nYFP and A~2A~R-cYFP (Fig. [1b](#Fig1){ref-type="fig"}). These results reinforce our previously proposed compact rhombus-shaped arrangement of protomers in which heteromerization of A~1~-A~2A~Het occurs via the TM5/6 interface (Fig. [1f](#Fig1){ref-type="fig"}). The fluorescence decrease induced by TM4 A~2A~R peptide indicates that the correct homomerization is a requisite for A~1~-A~2A~Het formation and/or that the TM4 peptide interferes with interactions of the TM4 of the external protomer of the A~2A~R homodimer with the internal protomer of the A~1~R homodimer (Fig. [1f](#Fig1){ref-type="fig"}) \[[@CR5]\]. Next, we evaluated whether receptor activation, by the A~1~R-selective agonist N^6^-cyclopentyladenosine (CPA), the A~2A~R-selective agonist 4-\[2-\[\[6-Amino-9-(N-ethyl-β-D-ribofuranuronamidosyl)-9H-purin-2-yl\]amino\]ethyl\] benzenepropanoic acid (CGS-21680), or both, modify the heteromer TM interface. As clearly shown in Figs. [1c--e](#Fig1){ref-type="fig"}, none of the agonists, used either individually (Figs. [1c, d](#Fig1){ref-type="fig"}) or in combination (Fig. [1e](#Fig1){ref-type="fig"}), modified the effect of the TM peptides relative to the ligand-free experiments. Therefore, no rearrangements of the TM interface in the A~1~-A~2A~Het occurred upon receptor activation.Fig. 1Effect of interference peptides on the A~1~-A~2A~Het structure determined by bimolecular fluorescence complementation (BiFC) assays. **a**--**e** BiFC assays were performed in HEK-293 T cells transfected with cDNAs (1 μg) for A~2A~R-nYFP, A~2A~R-cYFP, and non-fused A~1~R (**a**) or A~2A~R-cYFP and A~1~R-nYFP (**b**--**e**). Cells were pre-treated for 4 h with medium (control, broken lines) or with 4 μM of A~2A~R TM synthetic peptides (TM1 to TM7, green squares) or A~1~R synthetic peptides (TM5 to TM7, orange squares). Subsequently, they were left untreated (**a**, **b**) or activated for 10 min with the A~1~R agonist CPA (**c**, 100 nM), the A~2A~R agonist CGS-21680 (**d**, 100 nM), or both (**e**). Fluorescence was read at 530 nm. Mean ± SEM (13 experiments/treatment). One-way ANOVA followed by a Dunnett's multiple comparison test showed a significant fluorescence decrease over control values (\**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001). In each panel, there is a schematic representation of the BiFC pairs and conditions. (**f**) Schematic slice (left) and cartoon (right) representations of the A~1~-A~2A~Het built using the predicted experimental interfaces

Next, we investigated whether interference TM peptides, which are able to alter the quaternary structure of the A~1~-A~2A~Het as demonstrated by BiFC experiments, are also able to disrupt the heteromer. To do this, proximity ligation assays (PLA) were performed in HEK-293 T cells expressing A~1~R and A~2A~R. The PLA assay is a powerful technique to detect protein-protein interactions by assessing proximity between GPCR protomers with high resolution (\< 40 nm). A~1~-A~2A~Het was observed as red punctate staining (Fig. [2](#Fig2){ref-type="fig"}), whereas pretreatment of cells with TM4, TM5, TM6, and TM7 of A~2A~R did not decrease PLA staining (Fig. [2](#Fig2){ref-type="fig"}), indicating that interference peptides can alter the quaternary structure of the heteromer but cannot disrupt heteromerization.Fig. 2Effect of interference peptides on the A~1~-A~2A~Het structure determined by proximity ligation assay (PLA) confocal microscopy images (superimposed sections) in which A~1~-A~2A~Hets appear as red spots. HEK-293 T cells expressing A~1~R and A~2A~R were treated for 4 h with medium (control) or 4 μM of indicated TM peptides of A~2A~R; cell nuclei were stained with DAPI (blue); scale bars: 10 μm

The complex formed by G~s~, G~i~, and the A~1~-A~2A~Het as a signal transduction unit {#Sec4}
-------------------------------------------------------------------------------------

In order to test the ability of G~s~ and G~i~ proteins to interact with the A~1~-A~2A~Het, we used BRET assays \[[@CR7]\]. Cells were transfected with cDNAs of A~1~R-nYFP and A~2A~R-cYFP, which only upon complementation can act as a BRET acceptor (YFP), and *Renilla* luciferase (Rluc) as a BRET donor fused to either G~i~ (G~i~-Rluc) or G~s~ (G~s~-Rluc). We observed significant energy transfer (Additional file [1](#MOESM1){ref-type="media"}: Figure S1C), indicating that G~i~ and G~s~ are bound to their respective receptors in the A~1~-A~2A~Het.

Next, we tested whether the A~1~-A~2A~Het can signal through G~s~- and G~i~-dependent pathways by measuring cAMP levels in cells expressing both A~1~R and A~2A~R. The A~1~R-selective agonist CPA (100 nM, a concentration producing maximal effect), which was unable to modify cAMP levels in the absence of forskolin (Additional file [1](#MOESM1){ref-type="media"}: Figure S2A), decreased forskolin-induced cAMP due to its G~i~ coupling, and the A~2A~R-selective agonist CGS21680 (100 nM, a concentration producing maximal effect) increased cAMP due to a G~s~ coupling (Fig. [3a](#Fig3){ref-type="fig"}, control), indicating that both receptors signal via their cognate G protein. We performed the same experiments in cells treated with pertussis (PTX) or cholera (CTX) toxins, which impair G~i~- and G~s~-mediated signaling, respectively, and in cells transfected with minigenes that encode for peptides blocking the interaction of the receptor with the α subunits of G~i~ or G~s~ \[[@CR8]\]. As expected, we observed blockade of CPA-induced cAMP decrease by either PTX (Fig. [3a](#Fig3){ref-type="fig"}) or the G~i~-specific minigene (Fig. [3b](#Fig3){ref-type="fig"}), and blockade of CGS21680-induced cAMP increase by CTX (Fig. [3a](#Fig3){ref-type="fig"}) or the G~s~-specific minigene (Fig. [3b](#Fig3){ref-type="fig"}). Strikingly, PTX or G~i~-specific minigene (blocking G~i~-receptor interaction) also blocked the CGS21680-induced cAMP increase (Fig. [3a, b](#Fig3){ref-type="fig"}). Moreover, CTX or the G~s~-specific minigene (blocking G~s~-receptor interaction) also blocked the CPA-induced cAMP decrease (Fig. [3a, b](#Fig3){ref-type="fig"}). Control experiments using these agonists in cells expressing only A~1~R or A~2A~R did not show any crossover effect with either toxins or minigenes (Additional file [1](#MOESM1){ref-type="media"}: Figures S2B, C, E, F). These results demonstrate that both A~1~R- and A~2A~R-mediated signaling in the A~1~-A~2A~Het are dependent on the functional integrity of both G~i~ and G~s~ proteins. According to this, we observed by BRET experiments that the A~2A~R agonist-induced interaction between A~1~-A~2A~Het and G~s~ protein diminished in cells pre-treated with PTX (Additional file [1](#MOESM1){ref-type="media"}: Figure S1D). We hypothesize that this cross-communication could depend on the ability of α subunits of G~i~ and G~s~ coupled to the A~1~-A~2A~Het to establish mutual interactions (see below).Fig. 3Receptor signaling through the A~1~-A~2A~Het. Increases in cAMP percentage accumulation with respect to Fk-stimulated (**a**, **b**) or unstimulated (**c**) cells. A~1~-A~2A~Het-expressed cells pre-treated with medium, PTX (10 ng/mL overnight) or CTX (100 ng/mL for 1 h) before adding medium, forskolin (Fk, 0.5 μM), CPA (100 nM) plus/minus forskolin, CGS-21680 (100 nM) plus/minus forskolin, or CPA + CGS-21680. **b** Same assays in the absence or presence of 0.5 μg of cDNA corresponding to G~i~- or G~s~-α-subunit-related minigenes. Mean ± SEM (7 experiments/group). One-way ANOVA followed by Bonferroni's post-hoc test in panels **a**, **b** showed a significant effect over basal in samples treated with CGS-21680 or over forskolin in samples treated with CPA; in panel **c**, a significant effect is seen over basal (\**P* \< 0.05, \*\*\**P* \< 0.001). **d** The dynamic mass redistribution analysis was plotted as pm shifts versus time (Representative experiment, performed in triplicate). **e**, **f** Distances between the Cα atoms of Arg90 (α~i~AH domain) and Glu238 (Ras domain) of G~i~ (in yellow), Asn112 (α~s~AH) and Asn261 (Ras) of G~s~ (green), Arg90 (α~i~AH) and Asn112 (α~s~AH) (dark red), and between the center of masses of the binding sites of the G~i~-unbound A~1~R and G~s~-unbound A~2A~R protomers (black) obtained from two independent molecular dynamics (MD) simulations of A~1~-A~2A~Het in complex with G~i~ and G~s~ in which α~i~AH was modelled in the closed conformation (Additional file [1](#MOESM1){ref-type="media"}: Figure S6C) and α~s~AH was modelled in closed (**e**) or open (**f**) conformation. The computed distances are depicted as double arrows in the adjacent schematic representations. Representative snapshots of the models are shown. Code: G~i~-bound A~1~R/red, G~i~-unbound A~1~R/orange, G~s~-bound A~2A~R/light green, G~s~-unbound A~2A~R/dark green, α, β, and γ of G~i~/G~s~ in dark gray/light gray/purple, respectively, TM4/light blue, TM5/gray, α-helical α~i~AH/green, and α~s~AH/yellow. **g** MD simulations could not be performed for open conformations of α~s~AH and α~i~AH due to steric clash

To further test for a cross-communication between G proteins in the G~s~-G~i~-heterotetramer signaling unit, we resolved the real-time signaling signature by using a label-free method, based on optical detection of dynamic changes in cellular density following receptor activation \[[@CR9]\]. The magnitude of the signaling by CPA or by CGS 21680 significantly decreased when cells co-expressing both receptors were pre-treated with either PTX or CTX (Fig. [3d](#Fig3){ref-type="fig"}). This phenomenon was not observed in cells expressing only A~1~R (Additional file [1](#MOESM1){ref-type="media"}: Figure S2G) or A~2A~R (Additional file [1](#MOESM1){ref-type="media"}: Figure S2H). Again, these results indicate the simultaneous coupling of interacting G~s~ and G~i~ proteins within the A~1~-A~2A~Het.

Simultaneous activation of both A~1~R and A~2A~R with CPA and CGS21680 increased cAMP to similar levels to those obtained with CGS21680 alone and the signal of co-activated receptors was inhibited by both PTX and CTX (Fig. [3c](#Fig3){ref-type="fig"}). Therefore, A~1~R agonist was able to decrease forskolin-induced cAMP (Fig. [3a, b](#Fig3){ref-type="fig"}) and yet was unable to decrease A~2A~R-mediated increases of cAMP (Fig. [3c](#Fig3){ref-type="fig"}). Consequently, when both receptors are co-activated in the heterotetramer, only the A~2A~R-mediated, but not the A~1~R-mediated signaling occurs. This finding was confirmed in label-free experiments, showing that receptor co-activation with CPA and CGS 21680 did not increase the time-response curve with respect to the activation with CGS 21680 alone (Fig. [3d](#Fig3){ref-type="fig"} green and yellow lines, respectively).

It has been shown that the mechanism for receptor-catalyzed nucleotide exchange in G proteins involves a large-scale opening of the α-helical domain (αAH) of the α-subunit, from the Ras domain, allowing GDP to freely dissociate \[[@CR10]--[@CR13]\]. Notably, our proposed model of the A~1~-A~2A~Het positions the α~i~AH and α~s~AH domains facing each other (Fig. [3e](#Fig3){ref-type="fig"}). The fact that both G~s~- and G~i~-specific toxins and G~s~- and G~i~-specific minigenes affect both G~s~- and G~i~-mediated coupling in the A~1~-A~2A~Het suggests that the proposed large-scale conformational changes of αAH domains is mutually dependent. We used molecular dynamics (MD) simulations of the A~1~-A~2A~Het in complex with G~s~ and G~i~ to evaluate intermolecular distances between the α~s~AH and α~i~AH domains when α~i~AH is in the closed conformation and α~s~AH is either in the open (Fig. [3e](#Fig3){ref-type="fig"}) or in the closed conformation (Fig. [3e](#Fig3){ref-type="fig"}f). In a previous report, double electron--electron resonance (DEER) distance distributions between spin labels attached to Arg90 (α~i~AH domain) and Glu238 (Ras domain) of G~i~ (the distance between Cα atoms is termed d\[Arg90α~i~-Glu238α~i~\] in the manuscript) or Asn112 (α~s~AH) and Asn261 (Ras) of G~s~ (d\[Asn112α~s~-Asn261α~s~\]) permitted to faithfully monitor the equilibrium within the open (distance of \~40 Å) and closed (\~20 Å) conformation of the αAH domain \[[@CR13]\]. Here, we measured the intermolecular distance between the α~s~AH and α~i~AH domains using Cα atoms of Arg90 of α~i~ and Asn112 of α~s~ (d\[Arg90α~i~-Asn112α~s~\]). This d\[Arg90α~i~-Asn112α~s~\] intermolecular distance between α~i~AH in the closed conformation (d\[Arg90α~i~-Glu238α~i~\]: 11 Å, yellow line in Fig. [3e](#Fig3){ref-type="fig"}) and α~s~AH in the closed conformation (d\[Asn112α~s~-Asn261α~s~\]: 14 Å, green line in Fig. [3e](#Fig3){ref-type="fig"}) has an average value of 108 Å for inactive A~1~-A~2A~Het (Fig. [3e](#Fig3){ref-type="fig"}, dark red line). Activation of A~2A~R would trigger the opening of α~s~AH (d\[Asn112α~s~-Asn261α~s~\]: 52 Å; Fig. [3f](#Fig3){ref-type="fig"}, green line), necessary for GDP/GTP exchange, decreasing the d\[Arg90α~i~-Asn112α~s~\] distance between α~i~AH and α~s~AH to 60 Å (Fig. [3f](#Fig3){ref-type="fig"}, dark red line). Although the results are based on a single trajectory, it is unlikely that additional replicates would change, in a significant manner, the distances reported from the simulations. Moreover, the differences between the distances are so substantial that results from more simulations would not have a significant impact. We hypothesize that a similar change occurs with activation of A~1~R. This indicates that both receptors can signal via their cognate G protein by opening their αAH domain. However, in the compact rhombus-shaped A~1~-A~2A~Het model, simultaneous opening of both αAH domains (co-activation with CPA and CGS 21680) would not be possible due to a steric clash in such open conformations (Fig. [3g](#Fig3){ref-type="fig"}). Due to this steric clash, MD simulations of this open α~i~AH-open α~s~AH conformation in the absence of interference peptides (see below) cannot be performed.

Altering the heteromer interface of A~1~-A~2A~Het enables simultaneous G~i~ and G~s~ signaling {#Sec5}
----------------------------------------------------------------------------------------------

Next, we investigated whether the correct formation of the A~1~-A~2A~Het is a necessary condition for the crosstalk between the G~s~- and G~i~-signaling units using the interference peptides (TM4, TM5 and TM6 of A~2A~R, which alter receptor heterodimerization, and TM7 as a negative control). Remarkably, pretreatment of cells expressing A~1~-A~2A~Het with the interference peptides did not change receptor signaling when only one receptor is activated (Fig. [4a](#Fig4){ref-type="fig"}). Interestingly, in the presence of TM4, TM5 and TM6 peptides, simultaneous activation of both A~1~R and A~2A~R with CPA and CGS21680, respectively, allows CPA to decrease CGS21680-stimulated cAMP (Fig. [4a](#Fig4){ref-type="fig"}), in contrast to experiments in the absence of either interference peptides (Fig. [4a](#Fig4){ref-type="fig"}, control) or TM7 used as a negative control (Fig. [4a](#Fig4){ref-type="fig"}). Moreover, this decrease in cAMP accumulation in the CPA/CGS co-stimulated condition is mediated by activation of the A~1~R/G~i~ pathway as, in the presence of TM peptides, a selective A~1~R antagonist or the treatment with PTX blocks the CPA-induced effect (Additional file [1](#MOESM1){ref-type="media"}: Figure S2D). Thus, modification of the quaternary structure of the A~1~-A~2A~Het with peptides that penetrate within the heteromer interface abolishes inhibition of A~1~R by A~2A~R in the G~s~-G~i~-heterotetramer signaling unit. These experimental results suggest that synthetic peptides inserted between A~1~R and A~2A~R protomers, which are not able to disrupt the heteromer as seen by PLA (Fig. [2](#Fig2){ref-type="fig"}), increase the distance between G~i~ and G~s~. This would allow the simultaneous opening of α~i~AH and α~s~AH domains for GDP dissociation. In order to verify this hypothesis, we modeled the A~1~-A~2A~Het with the TAT-fused peptide TM6 altering the heteromer interface between A~1~R and A~2A~R, in complex with G~s~ (open α~s~AH, d\[Asn112α~s~-Asn261α~s~\]: 56 Å; Fig. [4b](#Fig4){ref-type="fig"}, green line) and G~i~ (open α~i~AH, d\[Arg90α~i~-Glu238α~i~\]: 52 Å; Fig. [4b](#Fig4){ref-type="fig"}, yellow line). Due to the insertion of TM6, the distance between the binding site of A~1~R and A~2A~R increases by 17 Å, from 14 Å in the absence of TM6 (Fig. [3e, f](#Fig3){ref-type="fig"}, black line) to 31 Å in the presence of TM6 (Fig. [4b](#Fig4){ref-type="fig"}, black line). This increase in the distance between heteromers also moves the intracellular α~i~AH and α~s~AH domains apart, thus permitting their simultaneous opening (d\[Arg90α~i~-Asn112α~s~\]: 10 Å; Fig. [4b](#Fig4){ref-type="fig"}, dark red line) for GDP/GTP exchange.Fig. 4Effect of interference peptides on receptor signaling. **a** cAMP production was determined in HEK-293 T cells transfected with 0.4 μg of A~1~R and A~2A~R cDNAs. Cells were treated for 4 h with medium (control) or with 4 μM A~2A~R TM synthetic peptides (TM1 to TM7, see Methods). Cells were unstimulated (basal, dotted line) or stimulated with forskolin (Fk, 0.5 μM, gray bars), with forskolin and the A~1~R agonist CPA (100 nM, black bars), the A~2A~R agonist CGS-21680 (100 nM, white bars), or with CPA and CGS-21680 (striped bars). Increases in cAMP percentage accumulation in relation to unstimulated cells. Mean ± SEM (7 experiments/condition). One-way ANOVA followed by Bonferroni's post-hoc test showed a significant effect over basal in samples treated with CGS-21680 or CGS-21680 plus CPA, or over forskolin in samples treated with CPA (\**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001). One-way ANOVA followed by Bonferroni's post-hoc test showed a significant effect over control in the absence of peptide (&*P* \< 0.05, &&*P* \< 0.01). **b** Intermolecular distances (depicted as double arrows in the adjacent schematic representation) were obtained from MD simulations of A~1~-A~2A~Het in complex with G~i~ and G~s~ (α~i~AH and α~s~AH were modeled in the open conformation, see Additional file [1](#MOESM1){ref-type="media"}: Figure S2B) in the presence of the TAT-fused TM6 peptide, which alters the heteromer interface between A~1~R and A~2A~R. A representative snapshot of the molecular model is shown, viewed from the intracellular site. The TAT-TM6 peptide is shown in purple, whereas the color code of the depicted proteins is as in Fig. [3](#Fig3){ref-type="fig"}

A~1~-A~2A~Het as an adenosine concentration-sensing device {#Sec6}
----------------------------------------------------------

In order to illustrate the molecular device allowing adenosine to signal by one or the other receptor \[[@CR4]\], we measured cAMP levels at increasing concentrations of adenosine in cells expressing the A~1~-A~2A~Het (Fig. [5a](#Fig5){ref-type="fig"}). Due to the higher affinity for the hormone, adenosine at a low concentration (30 nM) binds predominantly to A~1~R and engages a G~i~-mediated signaling, which significantly decreases forskolin-induced cAMP accumulation. At higher concentrations, adenosine progressively binds to A~2A~R, which engages a G~s~-mediated signaling. At high adenosine concentrations, full occupancy of both A~1~R and A~2A~R leads to marked increases in cAMP levels compatible with G~s~ activation and blockade of G~i~, as depicted in the schemes of Fig. [5a](#Fig5){ref-type="fig"}. In these conditions, full active A~2A~R can increase cAMP over the forskolin-induced levels whilst the progressive blockade of A~1~R by A~2A~R cannot reduce cAMP accumulations. To demonstrate such blockade of A~1~R actions by A~2A~R, we performed the experiments in the presence of a peptide (A~2A~R TM6) that inserts into the heteromer interface (Fig. [5b](#Fig5){ref-type="fig"}). In the presence of the peptide, the device lost its concentration-sensing properties. In fact, high adenosine concentrations, in which both receptors are fully occupied and functional, led to a null response, i.e., the A~2A~R-mediated increase in forskolin-stimulated cAMP is counteracted by a similar G~i~-mediated decrease of cAMP. Upon heteromer structure alteration by TM6, the A~2A~R becomes unable to block A~1~R-mediated signaling.Fig. 5A~1~-A~2A~Het as an adenosine concentration-sensing device. A~1~-A~2A~Het-expressed cells were treated for 4 h with medium (**a**) or with 4 μM of the synthetic A~2A~R TM6 peptide (**b**). Cells were stimulated with forskolin (Fk, 0.5 μM, red broken line) and adenosine at increasing concentrations (30--3000 nM, black bars). cAMP levels were expressed as percentage over unstimulated cells (basal, 100%). Mean ± SEM of (7 experiments/condition). One-way ANOVA followed by a Dunnett's multiple comparison tests showed statistical differences relative to cells stimulated only with forskolin (\*\**P* \< 0.01, \*\*\**P* \< 0.001). Bottom panels show schemes that may provide an explanation of the results obtained at each adenosine concentration. (1) The higher affinity of adenosine for A~1~R than for A~2A~R is illustrated by the size of the black lines at the binding site (adenosine is shown as gray rectangles). (2) Adenosine-induced A~1~R and A~2A~R activation are depicted as arrows in pink and green, respectively, starting at the binding site of each receptor. (3) A~1~R-induced G~i~ activation and A~2A~R-induced G~s~ activation, with the corresponding decrease/increase of cAMP, are depicted as arrows in pink and green, respectively. The inhibitory effect of G~s~ on G~i~-mediated signaling is shown as a red arrow. Width of arrows illustrates the magnitude of receptor or G protein activation or cross-talk. High adenosine concentrations increase the A~2A~R binding (gray rectangle), the adenosine-induced A~2A~R activation, the A~2A~R-induced G~S~ activation (green arrows) and the cross-talk among G proteins (red arrow), while decreasing the A~1~R-induced G~i~ activation (pink arrow) due to the cross-talk. In the presence of TM6 (in purple) the cross-talk among G proteins is lost, enabling simultaneous A~1~R-induced G~i~ activation (pink arrow) and A~2A~R-induced G~S~ activation (green arrow)

Recruitment of β-arrestin-2 by the A~1~-A~2A~Het {#Sec7}
------------------------------------------------

We used BRET assays to detect the interaction between a protomer and β-arrestin-2. Thus, cells were transfected with cDNAs of β-arrestin-2 fused to Rluc (Arr-Rluc) as the BRET donor and A~1~R or A~2A~R fused to YFP (A~1~R-YFP, A~2A~R-YFP) as the BRET acceptor. Control experiments in cells expressing only A~1~R-YFP or A~2A~R-YFP and Arr-Rluc show the ability of both receptors to recruit β-arrestin-2 (Additional file [1](#MOESM1){ref-type="media"}: Figure S3A) and the selectivity of each agonist (Additional file [1](#MOESM1){ref-type="media"}: Figure S3B). Similar experiments in cells additionally expressing non-fused A~2A~R (Arr-Rluc/A~1~R-YFP + A~2A~R) or non-fused A~1~R (Arr-Rluc/A~2A~R-YFP + A~1~R) were performed (Additional file [1](#MOESM1){ref-type="media"}: Figure S3B). Interestingly, in cells expressing Arr-Rluc, A~2A~R-YFP and non-fused A~1~R (control in Fig. [6a](#Fig6){ref-type="fig"} and Additional file [1](#MOESM1){ref-type="media"}: Figure S3B) or Arr-Rluc, A~1~R-YFP and non-fused A~2A~R (control in Fig. [6b](#Fig6){ref-type="fig"} and Additional file [1](#MOESM1){ref-type="media"}: Figure S3B), a similar degree of BRET was induced by CGS-21680 (white bars) or by CGS-21680 plus CPA (striped bars). This suggests that agonist binding to A~2A~R inhibits the CPA ability to stimulate β-arrestin-2 recruitment to A~1~R. In order to rationalize these results, we have used the recent crystal structure of rhodopsin bound to visual arrestin-1 \[[@CR14]\] to model the A~1~-A~2A~Het in complex with β-arrestin-2. The finger loop of arrestin, which adopts a short α-helix, is inserted into the intracellular cavity of the external protomer, whereas the C-domain of arrestin points towards the internal protomer of the homodimer. Figure [6c](#Fig6){ref-type="fig"} shows key intermolecular distances between the center of mass of the N- and C-domains of two arrestin molecules bound to A~1~R and A~2A~R obtained from MD simulations. These data suggest that the A~1~-A~2A~Het quaternary structure permits the binding of two arrestin molecules to the external protomers of both A~1~R and A~2A~R, similarly to the simultaneous binding of G~i~ and G~s~ to the heterotetramer. Moreover, similar simulations of A~1~-A~2A~Het in complex with G~i~ and β-arrestin-2 (Fig. [6d](#Fig6){ref-type="fig"}) show no steric clashes between G~i~ (bound to A~1~R) and arrestin (bound to A~2A~R). These results suggest that sustained activation of G~s~ (G~βγ~ moving away from G~αs~ to facilitate the interaction of G~αs~ with the catalytic domain of adenylate cyclase) by agonist binding to A~2A~R enables β-arrestin-2 recruitment to A~2A~R. As stated above, within the A~1~-A~2A~Het, CPA cannot activate G~i~ in the presence of the A~2A~R agonist CGS-21680 (Fig. [3](#Fig3){ref-type="fig"}) and, consequently, CPA does not trigger additional β-arrestin-2 recruitment to A~1~R (control in Figs. [6a, b](#Fig6){ref-type="fig"} and Additional file [1](#MOESM1){ref-type="media"}: Figure S3B).Fig. 6Effect of interference peptides on recruitment of β-arrestin-2. **a**, **b** Receptor agonist-induced β-arrestin-2 recruitment was measured by BRET. HEK-293 T cells were transfected with the cDNAs for β-arrestin-2-Rluc (Arr-Rluc, 0.5 μg cDNA) and either A~2A~-YFP (0.4 μg cDNA) and A~1~R (0.4 μg cDNA) (**a**) or A~1~-YFP (0.4 μg cDNA) and A~2A~R (0.4 μg cDNA) (**b**). Cells were untreated (control) or treated for 4 h with 4 μM A~2A~R TAT-TM synthetic peptides (TM4--7, see Methods) before addition of medium (basal, gray bars) or 100 nM of either the A~1~R agonist CPA (black bars), the A~2A~R agonist CGS-21680 (CGS, white bars), or both (striped bars). Positive BRET was expressed as milli-BRET units (see Methods). Mean ± SEM (7 experiments/condition). One-way ANOVA followed by Bonferroni's post-hoc test showed a significant effect over basal in samples treated with CGS-21680 or over forskolin in samples treated with CPA (\**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001). One-way ANOVA followed by Bonferroni's post-hoc test showed a significant effect of CPA + CGS-21680 over CGS-21680 treatments (&*P* \< 0.05, &&*P* \< 0.01). **c** Intermolecular distances between the center of masses of the N- and C-domains of the A~1~R-bound arrestin and of the A~2A~R-bound arrestin obtained from molecular dynamics (MD) simulations of A~1~-A~2A~Het in complex with two molecules of β-arrestin-2. **d** Intermolecular distances between the center of mass of the N- and C-domains of the A~2A~R-bound arrestin and the Cα atom of Glu238 (RAS domain) of G~i~ obtained from MD simulations of A~1~-A~2A~Het in complex with G~i~ bound to A~1~R and β-arrestin-2 bound to A~2A~R. These intermolecular distances are depicted as double arrows in the adjacent representative snapshots of the molecular models. Arrestin is shown in gray, whereas the color code of the depicted proteins is as in Fig. [3](#Fig3){ref-type="fig"}

Using the TAT-fused synthetic peptides we investigated whether the quaternary structure of the A~1~-A~2A~Het determines its putative selective A~2A~R-dependent β-arrestin-2 recruitment. As a negative control, we first corroborated that TM4, TM5, and TM6 peptides of A~2A~R do not interfere with A~1~R-mediated signaling (Additional file [1](#MOESM1){ref-type="media"}: Figure S3C). Pretreatment of cells expressing Arr-Rluc, A~2A~R-YFP and non-fused A~1~R (Fig. [6a](#Fig6){ref-type="fig"}), or Arr-Rluc, A~1~R-YFP and non-fused A~2A~R (Fig. [6b](#Fig6){ref-type="fig"}) with TM4, TM5, and TM6 peptides, but not in the absence of peptides (control) or with the TM7 peptide (negative control), allowed the detection of positive BRET (recruitment of β-arrestin-2) not only when cells were treated with the A~2A~R-selective agonist CGS-21680 (white bars), but also when treated with the A~1~R-selective agonist CPA (black bars) (Figs. [6a, b](#Fig6){ref-type="fig"}). Importantly, when cells expressing Arr-Rluc, A~2A~R-YFP, and non-fused A~1~R were co-activated by CPA and CGS-21680 (striped bars), BRET measurement in the presence of TM4, TM5, or TM6 peptides, but neither in the absence of peptides nor in the presence of TM7 peptide, significantly increased relative to the values obtained by the action of a single agonist (Fig. [6a](#Fig6){ref-type="fig"}). The trend is similar in cells expressing Arr-Rluc, A~1~R-YFP, and non-fused A~2A~R, but not statistically significant (Fig. [6b](#Fig6){ref-type="fig"}). These results indicate that alteration of the A~1~R-A~2A~R heteromer interface within the A~1~-A~2A~Het allows simultaneous recruitment of β-arrestin-2 to A~1~R and A~2A~R when both receptors are activated. Interference peptides abolish cross-communication of G proteins, permitting CPA to activate G~i~ (G~βγ~ moving away from G~αi~) and recruitment of β-arrestin-2 to A~1~R, as well as G~s~ activation by CGS-21680 (G~βγ~ moving away from G~αs~) and simultaneous recruitment of β-arrestin-2 to A~2A~R.

The C-terminal domain of A~2A~R is responsible for the dominant A~2A~R-mediated signaling {#Sec8}
-----------------------------------------------------------------------------------------

Despite the apparent structural symmetry of the GPCR/G protein macromolecular complex, a major difference is the length of the intracellular C-terminal domain of adenosine receptors (16 amino acids in A~1~R versus 102 in A~2A~R). The short C-terminal tail of the A~1~R does not have any known specific function, while the C-terminus of A~2A~R, albeit dispensable for ligand binding \[[@CR15]\], dimerization \[[@CR16]\], and agonist induced cAMP signaling \[[@CR17]\], influences constitutive signaling \[[@CR18]\]. Due to the shorter C-terminus of A~1~R and the proposed orientation of the C-tail of A~2A~R toward α~s~AH (see Additional file [1](#MOESM1){ref-type="media"}: Figure S4a for details), as well as the proposed role of the C-terminal tail in downstream signaling cascade activation \[[@CR19]\], we speculated that the C-terminus of A~2A~R could modulate the prevailing G~s~-mediated signaling upon A~1~R and A~2A~R co-activation. To test this hypothesis, we engineered two A~2A~R mutants, one lacking most of the C-terminal end (A~2A~^ΔCT^R) and another lacking the last 40 amino acids (A~2A~^Δ40^R). First, we tested whether these truncated versions of A~2A~R could form heteromers with A~1~R. We observed similar BRET saturation curves in HEK-293 T cells expressing a constant amount of A~1~R-Rluc cDNA and increasing amounts of either A~2A~R-YFP, A~2A~^Δ40^R-YFP, or A~2A~^ΔCT^R-YFP, indicating that A~2A~^Δ40^R and A~2A~^ΔCT^R form heteromers with A~1~R (Fig. [7a](#Fig7){ref-type="fig"}; BRET~max~ in mU: 91 ± 3 A~2A~R, 99 ± 3 A~2A~^Δ40^R, and 90 ± 8 A~2A~^ΔCT^R). Heteromers were also detected by BiFC assays in HEK-293 T cells transfected with cDNAs for A~1~R-nYFP and A~2A~^ΔCT^R-cYFP (Fig. [7b](#Fig7){ref-type="fig"}, dashed line). In these cells, fluorescence was reduced in the presence of TM4, TM5, and TM6 peptides of A~2A~R (Fig. [7b](#Fig7){ref-type="fig"}). Thus, heteromerization of A~2A~^ΔCT^R with A~1~R occurs via the TM5/6 interface, similarly to the interaction of A~2A~R with A~1~R.Fig. 7Influence of A~2A~R C-terminal domain over signaling properties of A~1~-A~2A~Hets. **a** BRET in cells expressing constant A~1~-Rluc amount (0.4 μg cDNA) and increasing (0.1--0.7 μg cDNA) amounts of A~2A~^Δ40^R-YFP or A~2A~^ΔCT^R-YFP. Mean of milli-BRET units ± SEM (*n* = 7). **b** BiFC assays (fluorescence measured at 530 nm) were performed in cells expressing (1 μg cDNA) A~1~R-nYFP and A~2A~^ΔCT^R-cYFP and pre-treated for 4 h with medium or 4 μM A~2A~R-TM peptides (TM1--7). Mean ± SEM (13 experiments/treatment). One-way ANOVA followed by a Dunnett's multiple comparison test showed a significant fluorescence decrease over control values (\*\*\**P* \< 0.001). **c** HEK-293 T cells expressing A~1~R (0.4 μg cDNA) and A~2A~R (0.3 μg cDNA), A~2A~^Δ40^R (0.3 μg cDNA), or A~2A~^ΔCT^R (0.3 μg cDNA) were unstimulated (basal, dotted line) or stimulated with forskolin (Fk, 0.5 μM, gray bars), with forskolin and CPA (100 nM, black bars), CGS-21680 (CGS, 100 nM, white bars), or with CPA + CGS-21680 (striped bars). cAMP percentage accumulation over unstimulated cells. Mean ± SEM (7 experiments/group). One-way ANOVA followed by Bonferroni's post-hoc test: significant effect over basal in CGS-21680-stimulated samples or over forskolin-stimulated cells (\*\**P* \< 0.01, \*\*\**P* \< 0.001) or CPA + CGS-21680 over CGS-21680-stimulated cells (&&&*P* \< 0.001). **d** HEK-293 T cells expressing β-arrestin-2-Rluc (Arr-Rluc, 0.5 μg cDNA), A~1~-YFP (0.4 μg) and A~2A~R (0.3 μg), A~2A~^Δ40^R (0.3 μg), or A~2A~^ΔCT^R (0.3 μg). Cells stimulated with agonists as indicated. Mean ± SEM (7 experiments/condition). One-way ANOVA followed by the Bonferroni's post-hoc test: significant differences over unstimulated cells (\**P* \< 0.05, \*\*\**P* \< 0.001) or CPA-CGS-21680 over CGS-21680-stimulated cells (&*P* \< 0.05, &&*P* \< 0.01). **e** Molecular model of the A~2A~R homodimer in complex with G~s~. TMs involved in homodimerization: TM4/light blue and TM5/gray; color code of proteins is as in Fig. [3](#Fig3){ref-type="fig"}. C-tail of G~s~α-subunit-unbound A~2A~R protomer is near α~s~AH (shown in closed conformation)

We measured cAMP production in cells expressing A~1~R and wild-type or truncated A~2A~R receptors (Fig. [7c](#Fig7){ref-type="fig"}). Truncated A~2A~R were able to signal as wild-type receptors. Interestingly, the dominant G~s~-mediated signaling when A~1~R and A~2A~R were co-activated decreased progressively with the shortening of the A~2A~R C-tail (Fig. [7c](#Fig7){ref-type="fig"}, striped bars). In fact, CPA inhibited CGS-21680-induced cAMP accumulation when truncated receptors were expressed, showing that, in these heteromers, A~1~R were functional (Additional file [1](#MOESM1){ref-type="media"}: Figure S5). Figure [7e](#Fig7){ref-type="fig"} shows a detailed view of the orientation of the C-tail (102 amino acids, Gln311-Ser412) of both A~2A~R protomers in the A~1~-A~2A~Het, which was modeled as suggested for the OXER \[[@CR20]\], together with the structure of β-arrestin-2 in complex with V2 vasopressin receptor \[[@CR21]\]. It is important to note that the exact conformation of the A~2A~R C-tail cannot unambiguously be determined, thus, we only predict its orientation as explained in detail in Additional file [1](#MOESM1){ref-type="media"}: Figure S4. The fact that the C-tail of the α~s~-unbound A~2A~R protomer points toward the α~s~AH domain suggests that this C-tail is influencing the conformational changes required to open the α~s~AH, and thus controlling the balance between G~s~ and G~i~ activation. Next, we measured β-arrestin-2 recruitment by BRET assays in cells expressing A~1~R and wild-type or truncated A~2A~R receptors. In cells expressing non-fused A~1~R, Arr-Rluc and A~2A~R-YFP, A~2A~^Δ40^R-YFP, or A~2A~^ΔCT^R-YFP, the A~1~R agonist CPA could increase BRET values only when the heteromer is formed with A~2A~R-truncated receptors. In these conditions, co-activation with CPA and CGS-21860 induced a BRET increase higher than the one obtained with CGS-21680 alone (Fig. [7d](#Fig7){ref-type="fig"}). These results indicate that the selective A~2A~R-dependent β-arrestin-2 recruitment in the A~1~-A~2A~Het decreases progressively with the shortening of the A~2A~R C-tail (Fig. [7d](#Fig7){ref-type="fig"}).

Discussion {#Sec9}
==========

As previously reviewed \[[@CR2], [@CR3], [@CR22]\], the intercommunication between protomers of a GPCR heteromer can be observed at the level of agonist binding, ligand-induced cross-conformational changes between receptor protomers, and the binding of GPCR-associated proteins, including heterotrimeric G proteins and β-arrestins. The intercommunication between protomers is a consequence of a defined quaternary structure that is responsible for the specific functional characteristics of the heteromer. For GPCR heteromers, such as A~1~-A~2A~Het, constituted by receptors sensing the same hormone but producing opposite signaling effects, it is not obvious how a defined quaternary structure achieves this dual behavior. A~1~-A~2A~Het acts as a concentration-sensing device that allows adenosine to signal by one or the other coupled G protein (G~s~ or G~i~) to fine-tune modulate the release of neurotransmitters from presynaptic terminals. In the present study, we solved this question by discovering a new mechanism of signal transduction, a cross-communication between G~i~ and G~s~ in the A~1~-A~2A~Het guided by the A~2A~R C-terminal domain.

We have shown that cross-communication between G~i~ and G~s~ proteins involves the formation of a GPCR heterotetramer (i.e., one homodimer of A~1~R and one of A~2A~R) that has a 2:2:1:1 (A~2A~R:A~1~R:G~s~:G~i~) stoichiometry. From our data, it is deduced that the cross-talk between G~i~ and G~s~ resides on the structural constraints surrounding the mechanism for GDP/GTP exchange, which involves the opening of the αAH domain of the α-subunit of any given G protein. We propose that cross-communication in the G~s~-G~i~-heterotetramer signaling unit is a property associated with a specific quaternary structure, the compact rhombus-shaped A~1~-A~2A~Het (the TM4/5 interface for homodimerization and the TM5/6 interface for heterodimerization), which positions the α~i~AH and α~s~AH domains in close proximity, making their conformational changes mutually dependent in a way that simultaneous opening of both αAH domains would not be possible due to a steric clash in such open conformations. Alterations of this quaternary structure of the A~1~-A~2A~Het by insertion of synthetic peptides between A~1~R and A~2A~R blocks this cross-communication without disrupting the heteromer and permits simultaneous activation of G~i~ and G~s~ in the heteromer~.~ Since the cross-talk between G~i~ and G~s~ resides on the structural constraints imposed by defined TM interfaces in the heteromer, it is important to note that other heterotetramers, mainly those sensing different hormones and with a different quaternary structure, might not display this cross-communication among G proteins. Moreover, although, from a structural point of view, the A~1~-A~2A~Het is capable to recruit not only two G proteins but also two β-arrestins, the cross-talk between G~i~ and G~s~, in which G~s~ activation inhibits the simultaneous activation of G~i~, blocks A~1~R agonist-promoted arrestin recruitment. Alteration of the A~1~-A~2A~Het by insertion of synthetic peptides between A~1~R and A~2A~R facilitates simultaneous activation of G~i~ and G~s~ and the corresponding binding of two β-arrestins to A~1~R and A~2A~R. Our finding that G~i~ is dependent on G~s~-mediated signaling strengthens the conclusion that cross-talk across G proteins is a potentially important functional property of GPCR heteromers. Remarkably, when both receptors are co-activated in this heterotetramer, only A~2A~R-mediated, but not A~1~R-mediated signaling occurs. We show that the ability of blunting A~1~R-mediated signaling when G~s~ is engaged is dependent of the long C-terminus of the A~2A~R. In the absence of A~2A~R activation by agonists, or in the absence of the C-terminal domain of A~2A~R, the A~1~R-mediated signaling via G~i~ is totally functional. The most straightforward hypothesis is that the opening of α~s~AH parallels a movement of the C-tail to block the opening of α~i~AH.

Adenosinergic signaling in mammalians is important for energy and temperature homeostasis and for neuroregulation. Multiplicity of adenosine actions is due to a balance between the expression of specific receptors and producing/degrading enzymes and to the biological diversity due to a membrane network established by the interaction among purinergic receptors \[[@CR23]\]. Ciruela et al. \[[@CR4]\] first identified the occurrence of heteromers formed by A~1~R-G~i~- and A~2A~-G~s~-coupled adenosine receptors that participate in the regulation of glutamate release by neurons projecting from the cortex to the striatum. The same A~1~-A~2A~Het can be found in astrocytes modulating the transport of γ-amino butyric acid (GABA) \[[@CR24]\]. Differently from the modulation of neuronal glutamate release, the A~1~R-G~i~-coupled receptor activates and the A~2A~R-G~s~-coupled receptor inhibits the modulation of GABA transport. Under conditions of high extracellular adenosine concentrations, such as hypoxic conditions \[[@CR25]\], the nucleoside will bind to both the high (A~1~R) and the low (A~2A~R) affinity receptors in the heteromer, and the predominant A~2A~R-mediated signaling via G~s~ will result in counteraction of astrocytic GABA transport. Our results show that the asymmetric signaling is possible because the long C-terminus of A~2A~R blunts G~i~-mediated signaling. We have therefore elucidated the mechanism by which the A~1~-A~2A~Het functions as an adenosine concentration-sensing device that can promote even opposite signaling responses depending on the extracellular concentration of adenosine. The molecular mechanism involves the C-terminal domain of the activated G~s~-coupled A~2A~R, which hinders the activation of A~1~R coupled to G~i~.

Conclusions {#Sec21}
===========

Using a convergent approach including biochemical, biophysical, cell biology, and molecular biology techniques, together with in silico molecular models, we here provide the mode of action of a membrane receptor complex that responds depending on the concentration of adenosine, a hormone and a neuroregulatory molecule. The concentration sensor is a heteromer composed of four adenosine receptors (two A~1~ and two A~2A~) and two G proteins (Gi and Gs). Despite Gi sits underneath the A~1~ receptor dimer and Gs sits underneath the A~2A~ receptor dimer, both G proteins do interact and are able to convey allosteric regulation depending on how the functional unit is activated. At low adenosine concentrations Gi is engaged via A1 activation without affecting/engaging Gs signaling. At higher concentrations Gs is engaged via A~2A~ activation, and this engagement blocks Gi-mediated signaling. The reason why a rhombus-shaped apparently symmetric structure results in asymmetric signaling is due to the long C-terminal tail of the A~2A~ receptor. In fact, both deletion of the C-terminal end or treatment with interfering peptides derived from the sequence of TM segments of the receptors impair allosteric cross-interaction between receptors and G proteins within the macromolecule, and the device loses its concentration sensing properties.

Methods {#Sec10}
=======

Cell culture and transient transfection {#Sec11}
---------------------------------------

HEK-293 T cells were grown at 37 °C in in Dulbecco's modified Eagle's medium (DMEM) (Gibco) supplemented with 2 mM L-glutamine, 100 U/mL penicillin/streptomycin, and 5% (v/v) heat inactivated fetal bovine serum (all supplements were from Invitrogen, Paisley, Scotland, UK). Cells were transiently transfected with cDNA corresponding to receptors, fusion proteins, A~2A~R mutant constructs, or minigene vectors using polyethylenimine (Sigma-Aldrich, Cerdanyola del Vallés, Spain) as described elsewhere \[[@CR7]\].

Expression vectors, A~2A~R mutants and minigenes {#Sec12}
------------------------------------------------

Sequences encoding amino acid residues 1--155 or 155--238 of YFP-Venus protein, were subcloned in pcDNA3.1 to obtain the YFP Venus hemi-truncated proteins (nYFP and cYFP). The human cDNAs for A~2A~R, mutant A~2A~R, A~1~R, and Gi or Gs proteins cloned into pcDNA3.1, were amplified without their stop codons using sense and antisense primers harboring unique EcoRI and BamHI sites to subclone receptors in pcDNA3.1RLuc vector (p*RLuc*-N1 PerkinElmer, Wellesley, MA, USA) and EcoRI and KpnI to subclone receptors in pEYFP-N1 (enhanced yellow variant of GFP; Clontech, Heidelberg, Germany), pcDNA3.1-nVenus, or pcDNA3.1-cVenus vectors. The amplified fragments were subcloned to be in-frame with restriction sites of the corresponding vectors to give the plasmids that express receptors fused to RLuc, YFP, nYFP or cYFP on the C-terminal end (A~1~R-Rluc, A~2A~R-Rluc, Gi-RLuc, Gs-RLuc, A~1~R-YFP, A~2A~R-YFP, A~2A~^Δ40^R-YFP, A~2A~^ΔCT^R-YFP, A~1~R-nYFP, A~2A~-nYFP, and A~2A~-cYFP). Expression of constructs was tested by confocal microscopy and the receptor-fusion protein functionality by second messengers, ERK1/2 phosphorylation and cAMP production as described previously \[[@CR4], [@CR26]--[@CR28]\]. Mutants with a deletion of aa 372 to aa 412 (A~2A~^Δ40^R) or aa 321 to aa 412 (A~2A~^ΔCT^R) on the C-terminal domain of A~2A~R were generated as previously described \[[@CR29]\]. "Minigene" plasmid vectors are constructs designed to express relatively short polypeptide sequences following their transfection into mammalian cells. Here, we used minigene constructs encoding 11 amino acid residues from the C-terminus sequence of α subunit of G~i1/2~ or G~s~. The peptide coded by every minigene inhibits the coupling of the G (G~i1/2~ or G~s~) protein to the receptor and, consequently, it inhibits the G-protein-mediated cellular response, as previously described \[[@CR8]\]. The cDNA encoding the last 11 amino acids of human G~α~ subunit corresponding to G~i1/2~ (IKNNLKDCGLF) or G~s~ (QRMHLRQYELL), inserted in a pcDNA 3.1 plasmid vector, was generously provided by Dr. Heidi Hamm.

TAT-TM peptides {#Sec13}
---------------

Peptides with the sequence of the TM of A~1~R and A~2A~R fused to the HIV TAT peptide (YGRKKRRQRRR) were used as oligomer-disrupting molecules (synthesized by Genemad Synthesis Inc. San Antonio, TX, USA). The cell-penetrating TAT peptide allows intracellular delivery of fused peptides \[[@CR6]\]. The TAT-fused TM peptide can then be inserted effectively into the plasma membrane because of the penetration capacity of the TAT peptide and the hydrophobic property of the TM moiety \[[@CR30]\]. To obtain the right orientation of the inserted peptide, the HIV-TAT peptide was fused to the C-terminus or to the N-terminus as indicated:MEYMVYFNFFVWVLPPLLLMVLIYLYGRKKRRQRRR for TM5 of A~1~R, RRRQRRKKRGYLALILFLFALSWLPLHILNCITLF for TM6 of A~1~R, ILTYIAIFLTHGNSAMNPIVYAFRIYGRKKRRQRRR for TM7 of A~1~R, VYITVELAIAVLAILGNVLVCWAVWYGRKKRRQRRR for TM1 of A~2A~R, YGRKKRRQRRRYFVVSLAAADIAVGVLAIPFAITI for TM2 of A~2A~R, LFIACFVLVLTQSSIFSLLAIAIYGRKKRRQRRR for TM3 of A~2A~R, YGRKKRRQRRRAKGIIAICWVLSFAIGLTPMLGW for TM4 of A~2A~R, MNYMVYFNFFACVLVPLLLMLGVYLYGRKKRRQRRR for TM5 of A~2A~R, YGRKKRRQRRRLAIIVGLFALCWLPLHIINCFTFF for TM6 of A~2A~R, LWLMYLAIVLSHTNSVVNPFIYAYYGRKKRRQRRR for TM7 of A~2A~R.YGRKKRRQRRRILGIWAVSLAIMVPQAAVME for TM4 of OX~1~R, SSFFIVTYLAPLGLMAMAYFQIFYGRKKRRQRRR for TM5 of OX~1~R, YASFTFSHWLVYANSAANPIIYNFYGRKKRRQRRR for TM7 of OX~1~R

Bimolecular fluorescence complementation assay (BiFC) {#Sec14}
-----------------------------------------------------

HEK-293 T cells were transiently transfected with equal amounts of the cDNA for fusion proteins of the hemi-truncated Venus (1 μg of each cDNA). At 48 h after transfection, cells were treated for 4 h at 37° with medium or TAT peptides (4 μM) before plating 20 μg of protein in 96-well black microplates (Porvair, King's lynn, UK). To quantify reconstituted YFP Venus expression, fluorescence at 530 nm was read in a Fluoro Star Optima Fluorimeter (BMG Labtechnologies, Offenburg, Germany) equipped with a high-energy xenon flash lamp, using a 10 nm bandwidth excitation filter at 400 nm reading. Protein fluorescence expression was determined as fluorescence of the sample minus the fluorescence of cells not expressing the fusion proteins (basal). Cells expressing receptor-cVenus and nVenus or receptor-nVenus and cVenus showed similar fluorescence levels than untransfected cells.

Bioluminescence resonance energy transfer (BRET) {#Sec15}
------------------------------------------------

HEK-293 T cells were transiently transfected with a constant amount of cDNA for Rluc fusion proteins and increasing amounts of cDNA for YFP fusion proteins. At 48 h after transfection, 20 μg of cell suspension were plated in 96-well black microplates for fluorescence detection or in 96-well white microplates for BRET readings and Rluc quantification. YFP fluorescence at 530 nm was quantified in a Fluoro Star Optima Fluorimeter as described above. BRET signal was collected 1 min after addition of 5 μM coelenterazine H (Molecular Probes, Eugene, OR, USA) using a Mithras LB 940. The integration of the signals detected in the short-wavelength filter at 485 nm and the long-wavelength filter at 530 nm was recorded. To quantify protein-RLuc expression, luminescence readings were also performed after 10 minutes of adding 5 μM coelenterazine H. The net BRET is defined as (long-wavelength emission/short-wavelength emission)--Cf, where Cf corresponds to long-wavelength emission/short-wavelength emission for the donor construct expressed alone in the same experiment. BRET is expressed as milli-BRET units (net BRET × 1000). To calculate maximum BRET (BRET~max~) from saturation curves, data were fitted to a nonlinear regression equation, assuming a single-phase saturation curve with GraphPad Prism software (San Diego, CA, USA).

Proximity ligation assay (PLA) {#Sec16}
------------------------------

HEK293T cells were grown on glass coverslips and fixed in 4% paraformaldehyde for 15 min, washed with phosphate-buffered saline containing 20 mM glycine, permeabilized with the same buffer containing 0.05% Triton X-100, and successively washed with tris-buffered saline. Heteromers were detected using the Duolink II in situ PLA detection Kit (OLink; Bioscience, Uppsala, Sweden) following supplier's instructions. A mixture of the primary antibodies (mouse anti-A~2A~R antibody (1:100; 05-717, Millipore, Darmstadt, Germany; RRID:AB_309931) and rabbit anti-A~1~R antibody (1:100; ab82477, Abcam, Bristol, UK; RRID: AB_2049141)) was used to detect A~1~-A~2A~Het together with PLA probes detecting mouse or rabbit antibodies. Then, samples were processed for ligation and amplification with a Detection Reagent Red and were mounted using a DAPI-containing mounting medium. Samples were analyzed in a Leica SP2 confocal microscope (Leica Microsystems, Mannheim, Germany) equipped with 405 nm and 561 nm laser lines. For each field of view, a stack of two channels (one per staining) and 4--6 Z-stacks with a step size of 1 μm were acquired. Images were opened and processed with Image J software (National Institutes of Health, Bethesda, MD, USA).

cAMP determination assays {#Sec17}
-------------------------

HEK-293 T cells expressing adenosine receptors were incubated for 4 h in serum-free medium containing 50 μM zardeverine. Cells were plated in 384-well white microplates (1500 cells/well), pre-treated with toxins or the corresponding vehicle for the indicated time, stimulated with agonists for 15 min before adding medium or 0.5 μM forskolin, and incubated for an additional 15 min. cAMP production was quantified by a TR-FRET (Time-Resolved Fluorescence Resonance Energy Transfer) methodology using the LANCE Ultra cAMP kit (PerkinElmer) and fluorescence at 665 nm was analyzed on a Pherastar Flagship Microplate Reader (BMG Labtech, Ortenberg, Germany).

Dynamic mass redistribution (DMR) assays {#Sec18}
----------------------------------------

The heteromer-induced cell signaling signature was determined using an EnSpire^®^ Multimode Plate Reader (PerkinElmer, Waltham, MA, USA) by a label-free technology. Refractive waveguide grating optical biosensors, integrated in 384-well microplates, allow extremely sensitive measurements of changes in local optical density in a detecting zone up to 150 nm above the surface of the sensor. Cellular mass movements induced upon receptor activation were detected by illuminating the underside of the biosensor with polychromatic light and measured as changes in wavelength of the reflected monochromatic light, which is a sensitive function of the index of refraction. The magnitude of this wavelength shift (in picometers) is directly proportional to the amount of DMR. Briefly, 24 h before the assay, cells were seeded at a density of 7500 cells per well in 384-well sensor microplates with 40 μL growth medium and cultured for 24 h (37 °C, 5% CO~2~) to obtain 70--80% confluent monolayers. Previous to the assay, cells were pre-treated with medium or toxins as indicated and incubated for 2 h in 40 μL per well of assay-buffer (HBSS with 20 mM HEPES, pH 7.15) in the reader at 24 °C. Thereafter, the sensor plate was scanned and a baseline optical signature was recorded prior to addition of 10 μL of receptor agonist dissolved in assay buffer containing 0.1% DMSO. DMR responses were monitored for at least 8000 s and data were analyzed using EnSpire Workstation Software v. 4.10.

Computational modeling {#Sec19}
----------------------

The structural model of the A~1~-A~2A~Het bound to G~s~ (closed α~s~AH domain) and G~i~ (closed α~i~AH domain) was taken from our previous work \[[@CR5]\]. This previous structural model contains a A~2A~R-based homology model of A~1~R. The structure of the adenosine A~1~R has recently been revealed \[[@CR31]\], showing a remarkably similar structure (Additional file [1](#MOESM1){ref-type="media"}: Figure S6A). This structure of A~1~R contains a TM4/5 dimer interface that is in close agreement with our model (Additional file [1](#MOESM1){ref-type="media"}: Figure S6B). An intermediate conformation (obtained using the g_morph tool of the GROMACS package \[[@CR32]\]) between the closed αAH domain (PDB id 1AZT) and the conformation observed in the crystal structure of the β~2~-AR in complex with Gs (PDB id 3SN6) was used to model the open αAH domain (Additional file [1](#MOESM1){ref-type="media"}: Figure S6C). This conformation is supported by DEER spectroscopy, deuterium-exchange and electron microscopy data \[[@CR11]--[@CR13]\]. The active state of β-arrestin-2 was built using a multi-template alignment combining the structure of the active β-arrestin-1 (PDB id 4JQI) \[[@CR21]\] and the structure of rhodopsin in complex with visual β-arrestin (PDB id 4ZWJ) \[[@CR14]\]. Structural models of the A~1~-A~2A~Het bound to β-arrestin-2 were modeled using the crystal structure of rhodopsin bound to β-arrestin (PDB id 4ZWJ) \[[@CR14]\]. The structure of TM6 of A~2A~R fused to the cell-penetrating TAT peptide was modeled from the structure of A~2A~R. Molecular models of the A~1~-A~2A~Het with the TAT-fused TM6 peptide, disrupting the heteromer interface between A~1~R and A~2A~R, in complex with G~s~ (open α~s~AH domain) and G~i~ (open α~i~AH domain), was built from the structure of A~1~-A~2A~Het. The conformation of the proximal C-tail of A~2A~R (Ser305-Ala317) was modeled based on squid rhodopsin \[[@CR33]\]. The remaining part of the C-tail (1Gly319--Ser412), cannot be unambiguously determined and it was modeled as suggested for the oxoeicosanoid receptor (OXER) \[[@CR20]\], together with the structure derived from the human V2 vasopressin receptor in complex with β-arrestin-2 \[[@CR21]\] (see Additional file [1](#MOESM1){ref-type="media"}: Figure S4 for details). Additional file [2](#MOESM2){ref-type="media"}: Table S1 shows the template structures used in the protein models. Modeller 9.12 was used to build these models \[[@CR34]\]. The molecular models of A~1~-A~2A~Het in complex with G~s~ and G~i~ or β-arrestin, in the absence or presence of the TAT-fused TM6 peptide, were embedded in a pre-equilibrated box containing a lipid bilayer (\~800 POPC molecules) with explicit solvent (\~110,000 waters) and 0.15 M concentration of Na^+^ and Cl^--^ (\~1800 ions). These initial complexes were energy-minimized and subsequently subjected to a 21 ns MD equilibration, with positional restraints on protein coordinates. These restraints were released and 500 ns of MD trajectory were produced at constant pressure and temperature. Computer simulations were performed with the GROMACS 4.6.3 simulation package \[[@CR32]\], using the AMBER99SB force field as implemented in GROMACS and Berger parameters for POPC lipids. This procedure has been previously validated \[[@CR35]\].

Additional files
================

 {#Sec20}

Additional file 1:**Figures S1--S6.Figure S1.** Control experiments on the effect of interfering peptides on the A~1~-A~2A~Het structure and G~s~ and G~i~ coupling to A~1~-A~2A~Het. **Figure S2.** Receptor signaling through A~1~R and A~2A~R. **Figure S3.** Recruitment of β-arrestin-2 by the A~1~-A~2A~Het. **Figure S4.** Modeling the orientation of the C-tail of A~2A~R. **Figure S5.** The influence of the C-terminal domain of A~2A~R in the signaling properties of the A~1~-A~2A~Het in the presence of pertussis toxin. **Figure S6.** Modeling A~1~R homodimer and α~s~AH and α~i~AH in closed and open conformations. (DOCX 5727 kb) Additional file 2:**Table S1.** List of target sequences and template structures used to construct the computer models of A~1~-A~2A~Het in complex with G~i~ and G~s~. (PDF 23 kb)
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